Edwards Lifesciences management check

EW · Health Care · Health Care Equipment · CEO Bernard J Zovighian

Filings as of

57
Management score, ranked 362nd of 487 · 45th of 60 in Health Care4 good · 1 to watch · 2 flaggedStrongest: clean books · Weakest: skin in the game · Best and worst run in Health Care →

The seven checks

  • Flag

    Have owners done well?

    Trailed its chosen peersOwners$93Peers$127

    What $100 became since fiscal 2021

    1728th
    Detail

    $100 invested at the start of fiscal 2021 grew to $93, against $127 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    8863rd
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.77 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Watch

    What does the CEO cost owners?

    1.6% of net income

    $17.5m pay · $1.1bn net income, FY2025

    0.1%1%3%10%
    3234th
    Detail

    $17.5m of reported pay in fiscal 2025, against $1.1bn of net income.

  • Flag

    Do they own the stock?

    CEO stake ≈ 0.7 years of pay

    121,945 shares ≈ $12.5m

    0.1y1y5y20y100y

    6 mo: ▲ $0 bought · ▼ $14.4m sold

    88th
    Detail

    The CEO holds 121,945 shares, directly or through trusts (unvested awards not counted): about 0.7 years of pay. 7 insiders sold $14.4m in the last six months and none bought. 10 of 21 sales ran on pre-arranged 10b5-1 plans.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 631m2025 · 586m

    Diluted shares −2.0% a year; flagged above +2%

    0%10%20%

    Stock pay 2.6% of revenue

    7467th
    Detail

    Diluted shares changed -2.0% a year over the last three fiscal years. Stock-based pay was 2.6% of revenue in the latest year.

  • Good

    Is leadership stable?

    9 leadership filings in 3 years

    9 filings under 8-K 5.02 in 3 years

    0101420+
    8056th
    Detail

    9 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed March 26, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
−$10.5m$10.5m$31.5m$10020212022202320242025$93$127

Pay tied most to •Underlying Revenue Growth

Other key measuresRelative TSR•Adjusted Earnings Per Share•KOD Measurement

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025—$17.5m$21.3m$4.7m$93$127$1.1bn
2024—$14.6m$9.2m$4.4m$81$117$1.4bn
2023—$12.9m$11.0m$5.0m$84$106$1.4bn
2022—$14.0m−$10.5m$4.2m$82$97$1.5bn
2021—$13.6m$31.5m$3.5m$142$119$1.5bn

Insiders and the CEO's stakeSelling

Shares held
121,945
At that filing's price
≈ $12.5m
Latest Form 4
Nov 9, 2026

7 insiders sold $14.4m in the last six months and none bought. 10 of 21 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldDonald E Jr BoboCVP,Strategy/Corp Development$7.0mNov 9, 2026
  • SoldDaveen ChopraCVP, TMTT, Surgical & IHFM$3.0mAug 26, 2026
  • SoldBernard J ZovighianCEO$2.7mNov 9, 2026
  • SoldWayne MarkowitzCVP, JAPAC$945kAug 26, 2026

Leadership and governance on file

20222023202420252026Leadership 11Votes 5
All 11 filings

Latest shareholder vote results: May 8, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $5.2bn returned to owners in buybacks and dividends, 53% of net income, and $695.9m of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$2.1bn$4.2bn20212022202320242025Shares631m624m609m599m586m
Show the figures
Fiscal year20212022202320242025
Revenue$5.2bn$4.5bn$5.0bn$5.4bn$6.1bn
Net income$1.5bn$1.5bn$1.4bn$4.2bn$1.1bn
Stock-based pay$109.3m$126.8m$139.4m$162.3m$158.1m
Buybacks$512.8m$1.7bn$879.6m$1.2bn$893.4m
Dividends—————
Diluted shares631m624m609m599m586m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.